Hympavzi (Marstacimab-Hncq) for Haemophilia

Overview
Hympavzi is approved by the U.S. Food and Drug Administration (FDA) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and children 12 and up with hemophilia A (congenital factor VIII deficiency) or hemophilia B (congenital factor IX deficiency), as long as they do not have inhibitors to these clotting factors. Hympavzi is also known by its drug name, marstacimab-hncq.

Marstacimab-hncq is a tissue factor pathway inhibitor (TFPI) antagonist. It works by blocking TFPI, which increases the body’s ability to form blood clots and helps reduce the frequency of bleeding episodes in people with hemophilia.

How do I take it?
Prescribing information states that Hympavzi is given as a subcutaneous (under the skin) injection. The treatment begins with a loading dose of two injections. One week after this loading dose, the maintenance dose is administered once per week on the same day. The dose may be increased if needed. Hympavzi should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Hympavzi include injection site reactions, headache, and pruritus (itchiness).

Rare but serious side effects may include thromboembolic events (blood clots) and hypersensitivity (allergic reactions). Hympavzi may also cause harm to a developing fetus.

For more information about this treatment, visit:

Hympavzi — Drugs.com

Hympavzi (Marstacimab-Hncq) Injection, for Subcutaneous Use — U.S. Food and Drug Administration